TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21353220

Group type: EXPERIMENTAL
Intervention: Postnatal education and support program (one‐to‐one educational session and follow‐up phone calls at two months and four months postpartum)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Routine postnatal care (control group)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Postnatal education and support program
Number of subjects: 90
Study: 18838271

Group type: EXPERIMENTAL
Intervention: Training with three different visual distortion lenses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Training with a single pair of visual distortion lenses
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham lenses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dynamic balance training
Number of subjects: 0
Study: 18065596

Group type: EXPERIMENTAL
Intervention: High fruit intake (approximately 5.7 ps/d)
Number of subjects: 32070

Group type: EXPERIMENTAL
Intervention: High intake of deep‐yellow vegetables, dark‐green vegetables, onions and garlic
Number of subjects: 32070

Group type: COMPARATOR
Intervention: Total vegetable intake
Number of subjects: 32070
Study: 14751925

Group type: EXPERIMENTAL
Intervention: Prophylactic blood transfusion
Number of subjects: 130

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Repeated TCD testing
Number of subjects: 130
Study: 11405507

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 523

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 523
Study: 9595926

Group type: EXPERIMENTAL
Intervention: SQA (quaternary ammonium antimicrobial compounds)
Number of subjects: 110

Group type: COMPARATOR
Intervention: CL (clindamycin 2% intravaginal cream)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: SQA
Number of subjects: 110

Group type: COMPARATOR
Intervention: CL
Number of subjects: 110
Study: 8129762

Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Cyclobenzaprine
Number of subjects: 208

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 208
Study: 3041876

Group type: EXPERIMENTAL
Intervention: Laminar flow air cleaner bed attachment (in use)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Non-use of laminar flow air cleaner bed attachment
Number of subjects: 13
Study: 31415468

Group type: EXPERIMENTAL
Intervention: Fear-Avoidance Beliefs Questionnaire (FABQ)
Number of subjects: 722

Group type: EXPERIMENTAL
Intervention: Single items of the FABQ
Number of subjects: 722

Group type: EXPERIMENTAL
Intervention: FABQ with added item 'I should not do my regular work with my present pain'
Number of subjects: 722
Study: 31099860

Group type: COMPARATOR
Intervention: No computerized cognitive training
Number of subjects: 272

Group type: COMPARATOR
Intervention: Wellness education
Number of subjects: 272

Group type: COMPARATOR
Intervention: Yoga
Number of subjects: 272
Study: 28109258

Group type: EXPERIMENTAL
Intervention: Epoetin beta (3.33×10^4 U, n=68)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Placebo (n=70)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Epoetin beta (3.33×10^4 U)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138
Study: 25499871

Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 848

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 848

Group type: EXPERIMENTAL
Intervention: Major bleeding (overall)
Number of subjects: 848

Group type: EXPERIMENTAL
Intervention: Intracranial hemorrhage (ICH)
Number of subjects: 848

Group type: EXPERIMENTAL
Intervention: Non-intracranial hemorrhage (non-ICH)
Number of subjects: 848

Group type: EXPERIMENTAL
Intervention: Major non-ICH bleeding
Number of subjects: 848

Group type: EXPERIMENTAL
Intervention: Stroke or MI following ICH
Number of subjects: 848

Group type: EXPERIMENTAL
Intervention: Management of major bleeds
Number of subjects: 848
Study: 23815103

Group type: EXPERIMENTAL
Intervention: BDP nasal aerosol 320 µg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BDP nasal aerosol 80 µg and 160 µg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 21829138

Group type: EXPERIMENTAL
Intervention: rcp45 vaccine (2 intranasal doses administered 4 to 10 weeks apart)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: rcp45 vaccine (2nd dose)
Number of subjects: 45

Group type: COMPARATOR
Intervention: cp45 vaccine (biologically derived)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: rcp45 vaccine
Number of subjects: 45
Study: 19468225

Group type: EXPERIMENTAL
Intervention: Ivabradine 5, 7.5, or 10 mg b.i.d. for 3 or 4 months
Number of subjects: 2425
Study: 16900817

Group type: EXPERIMENTAL
Intervention: Direct resin composite restorations (Clearfil AP-X)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Indirect resin composite restorations (Estenia)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Indirect technique
Number of subjects: 94

Group type: COMPARATOR
Intervention: Direct technique
Number of subjects: 94
Study: 14757687

Group type: EXPERIMENTAL
Intervention: Insulin at 2.5 U/h
Number of subjects: 32

Group type: COMPARATOR
Intervention: Normal saline and potassium (C)
Number of subjects: 32
Study: 11162694

Group type: EXPERIMENTAL
Intervention: Computed strain-gauge plethysmograph (CSGP) in Phase 1
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Computed strain-gauge plethysmograph (CSGP) using a modified protocol in Phase 2
Number of subjects: 322
Study: 9395153

Group type: EXPERIMENTAL
Intervention: Cognitive-behaviour therapy (CBT)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Combination of cognitive-behaviour therapy with a serotonergic antidepressant (fluvoxamine)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Non-responders at post-treatment
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Severity of symptoms, motivation for treatment, and dimensional score on the PDQ-R for cluster A personality disorder
Number of subjects: 99
Study: 8187446

Group type: EXPERIMENTAL
Intervention: Oral gold (6-9 mg auranofin by mouth daily)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Injectable gold (Solganal, aurothioglucose, 50-100 mg, intramuscularly, 2 to 4 weeks)
Number of subjects: 46
Study: 3025306

Group type: EXPERIMENTAL
Intervention: vidarabine
Number of subjects: 59

Group type: COMPARATOR
Intervention: acyclovir
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: NAb
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: LT
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: alpha interferon production
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: IgG and IgM antibody reactivity
Number of subjects: 59
Study: 29145626

Group type: EXPERIMENTAL
Intervention: Tobacco Treatment Advocates (TTAs) intervention with multiple visits, motivational interviewing, cessation counseling, and navigation to cessation resources
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Tobacco Treatment Advocates (TTAs) intervention
Number of subjects: 250

Group type: COMPARATOR
Intervention: Standard cessation materials and a one-time visit from a TTA providing basic counseling
Number of subjects: 250
Study: 28158212

Group type: EXPERIMENTAL
Intervention: nCPAP therapy for more than four hours per night, for more than 70% of nights
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: nCPAP therapy (entire group)
Number of subjects: 35

Group type: COMPARATOR
Intervention: sub-therapeutic CPAP pressure
Number of subjects: 35

Group type: COMPARATOR
Intervention: maintenance CPAP group
Number of subjects: 35
Study: 26232514

Group type: EXPERIMENTAL
Intervention: CCF 0.60‐0.79
Number of subjects: 2011

Group type: EXPERIMENTAL
Intervention: CCF ≥0.80
Number of subjects: 2011
Study: 21685346

Group type: EXPERIMENTAL
Intervention: Number sense intervention (8-week program, small-group, 30-min sessions, 3 days per week, total of 24 sessions)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Number sense intervention
Number of subjects: 121

Group type: COMPARATOR
Intervention: Business as usual contrast group
Number of subjects: 121
Study: 21565487

Group type: EXPERIMENTAL
Intervention: Celecoxib 400mg b.i.d. in addition to palliative chemotherapy
Number of subjects: 319

Group type: COMPARATOR
Intervention: Placebo in addition to palliative chemotherapy
Number of subjects: 319
Study: 17975234

Group type: EXPERIMENTAL
Intervention: Dexamethasone 8 mg i.v.
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control (normal saline 2 mL i.v.)
Number of subjects: 120
Study: 15916166

Group type: EXPERIMENTAL
Intervention: 400 mg/d vitamin E and 1000 mg/d vitamin C for 30 days
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo for 15 days
Number of subjects: 30
Study: 12351269

Group type: EXPERIMENTAL
Intervention: Propofol 2% MCT/LCT
Number of subjects: 30

Group type: COMPARATOR
Intervention: Propofol 2% LCT
Number of subjects: 30
Study: 9690396

Group type: EXPERIMENTAL
Intervention: Initial 100‐microg intravenous bolus followed by a continuous 25 microg/hr octreotide infusion (group I)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Continuous 25 microg/hr octreotide infusion without an initial bolus (group II)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Continuous placebo infusion (group III)
Number of subjects: 36
Study: 8130043

Group type: EXPERIMENTAL
Intervention: General anaesthesia
Number of subjects: 22

Group type: COMPARATOR
Intervention: Spinal anaesthesia
Number of subjects: 22
Study: 2478049

Group type: EXPERIMENTAL
Intervention: PCA with morphine (1.8 mg, n = 16)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: PCA with oxymorphone (0.3 mg, n = 16)
Number of subjects: 64

Group type: COMPARATOR
Intervention: PCA + BI with morphine (0.6 mg/hour, n = 16)
Number of subjects: 64

Group type: COMPARATOR
Intervention: PCA + BI with oxymorphone (0.1 mg/hour, n = 16)
Number of subjects: 64
Study: 31859967

Group type: EXPERIMENTAL
Intervention: Educational intervention (four modules, carried out in four occasions)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group (did not participate in educational sessions)
Number of subjects: 58
Study: 29493100

Group type: EXPERIMENTAL
Intervention: Mitiglinide 10 mg/voglibose 0.2 mg three times daily for 3 days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Glimepiride 1 mg once daily for 3 days
Number of subjects: 20
Study: 27607411

Group type: EXPERIMENTAL
Intervention: Combination therapy (methotrexate+sulfasalazine+hydroxychloroquine with prednisolone)
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Combination therapy with anti-TNF induction (infliximab)
Number of subjects: 234

Group type: COMPARATOR
Intervention: Combination therapy with placebo
Number of subjects: 234
Study: 24127364

Group type: COMPARATOR
Intervention: CET plus placebo
Number of subjects: 750

Group type: EXPERIMENTAL
Intervention: CET plus brivanib alaninate (BRIV)
Number of subjects: 750
Study: 22584733

Group type: EXPERIMENTAL
Intervention: Paclitaxel alone (PTX)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Docetaxel alone (DTX)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Anthracycline-cyclophosphamide followed by paclitaxel (ACP)
Number of subjects: 300

Group type: COMPARATOR
Intervention: AC followed by docetaxel (ACD)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Any taxane regimen
Number of subjects: 300

Group type: COMPARATOR
Intervention: Any regimen
Number of subjects: 300
Study: 23282652

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) for allergic rhinitis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) for asthma associated with rhinitis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) for atopic dermatitis, latex allergy, and hymenoptera hypersensitivity
Number of subjects: 0
Study: 18028578

Group type: EXPERIMENTAL
Intervention: Flexible laryngeal mask airway
Number of subjects: 120

Group type: COMPARATOR
Intervention: Reinforced tracheal tube
Number of subjects: 120
Study: 16118294

Group type: EXPERIMENTAL
Intervention: Dynamic soft tissue mobilisation (STM)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Classic soft tissue mobilisation (STM)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 45
Study: 12719883

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 49

Group type: COMPARATOR
Intervention: Saline + furosemide (40 mg after hydration)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Saline + mannitol (50 g mixed with cisplatin)
Number of subjects: 49
Study: 11061799

Group type: EXPERIMENTAL
Intervention: MMR vaccine
Number of subjects: 1162
Study: 8859177

Group type: EXPERIMENTAL
Intervention: Indomethacin suppository (50 mg) administered once or twice daily for 4 or 8 weeks
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Indomethacin suppository (50 mg)
Number of subjects: 8
Study: 1536727

Group type: EXPERIMENTAL
Intervention: Cyclosporin 6 mg/kg body wt. per day for 3 months and tapering doses over the next 3 months
Number of subjects: 40

Group type: COMPARATOR
Intervention: Chlorambucil at a cumulative dose of 8 mg/kg body wt.
Number of subjects: 40
Study: 6097125

Group type: EXPERIMENTAL
Intervention: Cefmenoxime (0.5 to 1 g every six hours)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Cefoxitin (1 to 2 g every six hours)
Number of subjects: 41
Study: 31303933

Group type: EXPERIMENTAL
Intervention: Postgraduate dissertations
Number of subjects: 231

Group type: COMPARATOR
Intervention: Control group (published papers)
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Undergraduate dissertations
Number of subjects: 231
Study: 29661873

Group type: EXPERIMENTAL
Intervention: Chloroquine
Number of subjects: 0
Study: 26821697

Group type: EXPERIMENTAL
Intervention: Cricoid pressure (CP)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham group
Number of subjects: 60
Study: 25461792

Group type: EXPERIMENTAL
Intervention: Videoconference-assisted ERP (VCT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Self-help ERP (S-H)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Wait-list condition (W-L)
Number of subjects: 30
Study: 22289129

Group type: EXPERIMENTAL
Intervention: Parental report of impulsivity in first-grade girls
Number of subjects: 119

Group type: COMPARATOR
Intervention: Conduct problems
Number of subjects: 119

Group type: COMPARATOR
Intervention: Oppositional defiant behavior
Number of subjects: 119
Study: 20846442

Group type: EXPERIMENTAL
Intervention: Mind Map (MM)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Standard Note-Taking (SNT)
Number of subjects: 131
Study: 17704023

Group type: EXPERIMENTAL
Intervention: n‐3 PUFA/gamma‐CD complex (660 mg EPA + 280 mg DHA/day)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (capsules containing essentially no n‐3 PUFA)
Number of subjects: 42
Study: 16178985

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg
Number of subjects: 1000
Study: 12045164

Group type: EXPERIMENTAL
Intervention: Aspirin 1.2 g orally 2 hours before vaccination
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Local intrabrachial aspirin 10 mg/min for 15 minutes
Number of subjects: 12
Study: 10402690

Group type: EXPERIMENTAL
Intervention: Observer perspective in social phobia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Observer perspective in agoraphobia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Observer perspective in blood/injury phobia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-social/non-anxiety-provoking situation
Number of subjects: 0
Study: 7794876

Group type: EXPERIMENTAL
Intervention: Foods containing added sugars
Number of subjects: 8

Group type: COMPARATOR
Intervention: Foods containing naturally-occurring sugars
Number of subjects: 8
Study: 2021561

Group type: EXPERIMENTAL
Intervention: Intensive treatment (test group, N=17)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Routine methods (control group, N=19)
Number of subjects: 36
Study: 7078985

Group type: EXPERIMENTAL
Intervention: Tilidine (Valoron)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Praziepam (Demetrin)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 30998551

Group type: EXPERIMENTAL
Intervention: Backward walking observational training
Number of subjects: 14

Group type: COMPARATOR
Intervention: Landscape observation + backward walking training
Number of subjects: 14
Study: 29663291

Group type: COMPARATOR
Intervention: Apatinib (oral administration)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 27062051

Group type: EXPERIMENTAL
Intervention: Olaparib
Number of subjects: 97

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Olaparib and Placebo
Number of subjects: 97
Study: 23437899

Group type: EXPERIMENTAL
Intervention: Manipulations of context salience and encoding strategy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Context effects on pair memory
Number of subjects: 0
Study: 21585410

Group type: EXPERIMENTAL
Intervention: 5mL midazolam
Number of subjects: 206

Group type: COMPARATOR
Intervention: 3mL midazolam
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Meperidine (not prefilled)
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Overall sedation
Number of subjects: 206
Study: 18834466

Group type: EXPERIMENTAL
Intervention: AF ablation
Number of subjects: 0

Group type: COMPARATOR
Intervention: SVT ablation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AF ablation with recurrent AF
Number of subjects: 0
Study: 17066580

Group type: EXPERIMENTAL
Intervention: Doppler sonography
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional sonography
Number of subjects: 100
Study: 12706704

Group type: EXPERIMENTAL
Intervention: Trivalent live, cold‐adapted influenza virus vaccine (CAIV‐T) co-administered with trivalent inactivated influenza virus vaccine (TVV)
Number of subjects: 2215

Group type: COMPARATOR
Intervention: Trivalent inactivated influenza virus vaccine (TVV) and placebo (TP)
Number of subjects: 2215
Study: 11115157

Group type: EXPERIMENTAL
Intervention: Polyethylene glycol‐coated liposomal doxorubicin hydrochloride (Doxil)
Number of subjects: 60
Study: 9112109

Group type: EXPERIMENTAL
Intervention: Speech recognition in noise
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Cognitive ability in elderly subjects
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Speech recognition in noise dysfunction in elderly subjects
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Performance differences between young and elderly subjects
Number of subjects: 50
Study: 1318765

Group type: EXPERIMENTAL
Intervention: Hepatitis A vaccine (group 1, 54 volunteers) at 0, 1, and 2 months
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Hepatitis A vaccine (group 2, 50 volunteers) at 0, 1, and 6 months
Number of subjects: 104

Group type: COMPARATOR
Intervention: Naturally infected subjects
Number of subjects: 104
Study: 3800819

Group type: EXPERIMENTAL
Intervention: Atropine sulfate (0.0, 0.5, 1.0, 2.0, and 4.0 X 75 kg‐1)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Ethanol (0.082% blood alcohol level)
Number of subjects: 20
Study: 29514524

Group type: EXPERIMENTAL
Intervention: Silicone gel
Number of subjects: 60

Group type: COMPARATOR
Intervention: Onion extract gel
Number of subjects: 60
Study: 26825736

Group type: EXPERIMENTAL
Intervention: cilnidipine
Number of subjects: 62

Group type: COMPARATOR
Intervention: amlodipine
Number of subjects: 62
Study: 24964176

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 10 mg co-administered with steady-state erythromycin in subjects with mild or moderate RI
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 10 mg co-administered with steady-state erythromycin in subjects with moderate RI
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rivaroxaban administered alone in RI subjects
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rivaroxaban co-administered with steady-state erythromycin in NRF subjects
Number of subjects: 0
Study: 23234606

Group type: EXPERIMENTAL
Intervention: Artesunate-mefloquine (AM)
Number of subjects: 310

Group type: COMPARATOR
Intervention: Artemether-lumefantrine (AL)
Number of subjects: 310
Study: 20198713

Group type: EXPERIMENTAL
Intervention: Pardoprunox (9‐45 mg/d, mean dose 23.8 mg/d)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Pardoprunox
Number of subjects: 139
Study: 18302208

Group type: EXPERIMENTAL
Intervention: Interpersonal therapy (IPT)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Pharmacotherapy with clinical management (PHT-CM)
Number of subjects: 102
Study: 18427286

Group type: EXPERIMENTAL
Intervention: Epsilon-aminocaproic acid (EACA) 5 g IV
Number of subjects: 60

Group type: COMPARATOR
Intervention: Aprotinin 1 x 10 KIU
Number of subjects: 60
Study: 15307936

Group type: EXPERIMENTAL
Intervention: Thyroid hormone replacement therapy (levothyroxine)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control group (7 healthy subjects)
Number of subjects: 7
Study: 11479247

Group type: EXPERIMENTAL
Intervention: Ramipril (up to 10 mg/d)
Number of subjects: 9297

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9297
Study: 9438110

Group type: EXPERIMENTAL
Intervention: Teflon piston with a shaft diameter of 0.4 mm
Number of subjects: 60

Group type: COMPARATOR
Intervention: Teflon piston with a shaft diameter of 0.3 mm
Number of subjects: 60
Study: 8106945

Group type: EXPERIMENTAL
Intervention: ePTFE membranes
Number of subjects: 12

Group type: COMPARATOR
Intervention: Connective tissue graft (CTG)
Number of subjects: 12
Study: 3307366

Group type: EXPERIMENTAL
Intervention: Digoxin plus nadolol (titrated from 20 to 120 mg daily)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Digoxin plus placebo
Number of subjects: 32
Study: 30661836

Group type: EXPERIMENTAL
Intervention: HydroVax-001 (1 mcg dose)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: HydroVax-001 (4 mcg dose)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 28679341

Group type: EXPERIMENTAL
Intervention: Empirical likelihood approach to covariate adjustment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Existing efficient adjusted estimators
Number of subjects: 0
Study: 27092472

Group type: EXPERIMENTAL
Intervention: Endovascular therapy plus intravenous tPA administration
Number of subjects: 196
Study: 25409546

Group type: EXPERIMENTAL
Intervention: Artesunate-amodiaquine (AS-AQ)
Number of subjects: 383

Group type: COMPARATOR
Intervention: Artemether-lumefantrine (AL)
Number of subjects: 383